Thunderstruck By OpenEvidence’s $12B Valuation? Don’t Be. 

OpenEvidence’s $12 billion valuation reflects investor confidence in its bottom-up, doctor-first model. It has driven rapid adoption, with more than 430,000 clinicians using the startup’s free AI medical search tool regularly. That scale is paired with targeted pharmaceutical advertising that’s already pushed the company past a $100 million revenue run rate. The post Thunderstruck By…

Read More

Clinical Trial Win Bolsters Blockbuster Prospects for Roivant Rare Disease Drug Licensed From Pfizer

Brepocitinib is on track for pivotal testing after meeting the goals of a proof-of-concept study in cutaneous sarcoidosis, a rare inflammatory skin disorder with no FDA-approved therapies. Roivant Sciences subsidiary Priovant Therapeutics licensed the dual JAK1 and TYK2 inhibitor from Pfizer. The post Clinical Trial Win Bolsters Blockbuster Prospects for Roivant Rare Disease Drug Licensed…

Read More

Newsom Tries To Thread Needle on Immigrant Health as Ambitions Turn National

As Gov. Gavin Newsom spars with President Donald Trump and courts national attention for a potential presidential bid, at home he’s catching flak from the left and the right on health care.  The California Democrat came into office promising to fight for “guaranteed health care for all,” and he came close to achieving it. Really close. But as it turns out, that’s easier said than done when you’re juggling chronic budget deficits, rising health care costs, and shrinking federal support.  Now he’s walking…

Read More